IMV Inc. Stock Toronto S.E.
Equities
IMV
CA44974L3011
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 30.6M 41.86M |
---|---|---|---|---|---|
Net income 2021 | -36M -49.25M | Net income 2022 | -38M -51.98M | EV / Sales 2021 | - |
Net cash position 2021 | 18.96M 25.94M | Net Debt 2022 | 7.67M 10.5M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.47
x | P/E ratio 2022 |
-0.53
x | Employees | 63 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.93% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 20-11-09 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 20-06-30 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 21-03-31 |
Markus Warmuth
BRD | Director/Board Member | 53 | 18-11-05 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |